期刊
BLOOD
卷 116, 期 24, 页码 5285-5288出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-03-272393
关键词
-
类别
资金
- Winship Cancer Institute of Emory University
- Leukemia & Lymphoma Society
- Multiple Myeloma Research Foundation
- Millennium
- Celgene
- Bristol-Myers Squibb
- Novartis
- Merck
In this report, we investigated the mechanism responsible for synergistic induction of myeloma cell apoptosis induced by the combination of tipifarnib and bortezomib. Immunofluorescence studies revealed that bortezomib alone resulted in an accumulation of puncta of ubiquitinated proteins that was further enhanced by the addition of tipifarnib. These data suggest inhibition of the degradation of bortezomib-induced aggresomes; and consistent with this possibility, we also observed an increase in p62SQSTM1 in cells treated with the combination. However, autophagy in these cells appears to be normal as LC3BII is present, and auto-phagic flux appears to be unaffected as demonstrated by the addition of bafilomycin A(1). Together, these data demonstrate that tipifarnib synergizes with bortezomib by inducing protein accumulation as a result of the uncoupling of the aggresome and autophagy pathways. (Blood. 2010;116(24):5285-5288)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据